Member Info for elrico

I have had an interesting exchange with SOH this evening. Some investors have misunderstood the company, the model and the significance of what is being developed under the market radar.

https://smallcompanychampiona88.substack.com/p/optibiotix-health-c89

https://smallcompanychampiona88.substack.com/p/skinbiotherapeutics-plc

https://knowledge.sharescope.co.uk/2021/06/25/equals-group-plc-are-they-making-a-comeback/

https://mobile.twitter.com/LEMMINGINVESTOR/status/1409573073104343060' target='window'>hTTps://mobile.twitter.com/LEMMINGINVESTOR/status/1409573073104343060
#EQLS

But, the analysts doesn't appear to have a good grasp of the business or parts of it.
https://twitter.com/LEMMINGINVESTOR/status/1407338343508107265

https://mobile.twitter.com/LEMMINGINVESTOR/status/1406624353911980033

https://smallcompanychampion3db.substack.com/

I first feature WHR at 115p.

https://mobile.twitter.com/LEMMINGINVESTOR

Farris,

There is no cure for psoriasis. Even so, before the company can make specific claims they will need to do clinical studies, not consumer studies.

As for marketing...I suspect SBTX will not need to throw any serious funds at this because Stuart has indicated various associations will be proactive in making their members aware of the probiotic. The USA association has over 8 million members. Do you imagine SBTX will struggle to obtain 15, 20, 30k subscriptions from them and UK, EU versions? I seriously doubt this. IMHO it will be a matter of how quickly they achieve this target (25k not a forecast). I am not willing to guestimate on this because it is akin to guestimating the future SP without revenue visibility.

The VIPs could well be the next big catalyst. I would not be attempting to second guess the timing. I'll be keeping a firm grip on my shares. I can add from profits from elsewhere if Lemmings offer an opportunity as they have with ORPH. Lemmings invested there are flushing free cash away based on the misunderstanding of dilution. So it comes as no shock to see profit-taking here or stops being trigger by those that bought the spike on the news.

You assume nothing from a number of "late-stage discussions" for CleanBiotix and Wondcare, any of which could land any day. As I keep saying, there is more to SBTX than the probiotic and cosmetics.

I also expect further data related to other skin conditions not mentioned in the RNS.

Listen to Stuart Ashman of SkinBioTherapeutics Plc by lemming investors on #SoundCloud
https://soundcloud.app.goo.gl/JJB5w

Listen to OptiBiotix Health CEO Stephen O'Hara by lemming investors on #SoundCloud
https://soundcloud.app.goo.gl/LtcUH

https://small-company-champion-investing.letterdrop.com/p/open-orphan-2

The author of the ShareScope article can be found https://smallcompanychampion3db.substack.com/p/de-la-rue

I'm having a little fun. I got a lot of stick when I arrived at £9.125m FY gross revenues @25k subs based on a £1 per day sachet. Even though 25,000 subs and £1 per day are not my numbers, or Stuarts forecast.

Like I said, attempts to quantify how many 100g jars 1 ltr of lysate can manufacture is almost impossible because the quantities change with the cosmetic products. It is far easier, and safer to work with estimates like 10% - 20% of Matrixyl market share of sales, which are believed to be between £250-300m.

This will not happen overnight. 10-12 global brands will be an exceptional start. I wonder what percentage of Sedermas sales these will a count for?

If I were to guess, I would say Croda will not use it with Matrixyl. The lysate is a direct competitor to Matrixyl.

I'm sure a lot of lab work would need to be done to test your thinking.

As I indicated in the interview...investor attention should shift to Croda/Sederma shortly. IMHO, this is more important to the company because of the potential, and reason as discussed with Stuart. There is potential for bonus commercial agreements also landing. A number of them were in late-stage discussions. However, the timing of these can not be judge because there will be more moving parts (partner signatures) than SBTX has, and these are usually taking longer than we investors anticipate.

Remember, the lysate is being scaled up!

"Having successfully scaled up capacity past 2 litres and 20 litres respectively, the planned scale-up to 600 litres will be completed in Q2 2021. In Q3, this will be followed by a final scale-up to 20,000 litres; the capacity required to mass-produce the SkinBiotix(R) product at industrial levels to supply Sederma's portfolio of 12,000+ global customers;

-- Commercial positioning work has begun with the schedule for early customer engagement being prepared for discussion with SkinBioTherapeutics."

It is challenging to determine how much products 1 ltr of lysate can produce because each cosmetic will have a different formulation and price point. All we know at this stage is are north of 10%. Matrixyl can be as much as 10% of the weight volume. If we use 10% of 100 ml/jar, = millions of 100 ml jars. Let's assume each jar is £25 @ 10% royalty... No, I best not. The last time I did this, it causes a lot of problems and the share price multi-bagged. ??

No worries. I try to help where I can.

Faris,

These were out of bounds. They have been discussed previously, but, they were down the track, so could be discussed as opportunities. I gather there are a number of "late-stage discussions" which means they are at a delicate stage. SBTX could drop a CleanBiotix deal at any time. Medi is a long way down the track. It is not a low hanging fruit but could attract a milestone/upfront payment. For me, the focus for investors/perspective should be on the probiotic(s) and cosmetics, because these will be launched this year. Then the production ramp-up in 2022 could be colossal for the company.

Thanks, Belgrano,

Of course, I would love to dedicate more time to the work I do for lemming investors, Small Company Champion, and now, ShareScope/Sharepad. I'm a few years away from this dream, unless our mutual friend deliver their potential withing 24/36 months.

I'll be uploading the video Sunday. A face for radio, you might say. ??

I eagerly await the cosmetic names. This period will be super exciting.

Good luck.

Marxist,

The strain has been well documents by the company; lactobacillus rhamnosus. SBTX own the mechanistic data to the formula and have filed a patent accordingly. Winclove have the right to manufacture and blend the bacteria. The bacterial strains are not owned by anyone; they help an international bank for any company to use. It is the mechanistic/blend that is key.

If you know anything about filing a patent or IP, you should know a detailed mechanism of action is needed. UoM is the leading dermatology university, lead me a work opinion leader, a go-to professor in dermatology. Universities are probably more practised in filing IP/Patents than companies because they are innovators and they protect their IP/Patents. Stuart Ashman is on record explaining his strategy is protecting both IP/Patents. If you fear otherwise, you should not invest, simple.

I suggest you put aside £35 of the £500k and swing by https://smallcompanychampiona88.substack.com/
This guy is awesome, no, truly he is. ??

You will learn a lot, I promise. ??????

SOH was asked very searching questions by me; he answered them as best as I dare expect. The audio is available @ https://smallcompanychampiona88.substack.com/p/optibiotix-health-03b